New frontiers in TAVI: have we reached them?
Sponsored by Edwards Lifesciences
TAVI
Symposium with Recorded case
Room 4
Anchorperson: Victoria Delgado
Spokesperson: Bernard Prendergast
Discussants: Helene Eltchaninoff, Philippe Genereux, Julia Mascherbauer, Mariuca Nicotera, Philippe Pibarot, Hendrik Treede
Watch this session if you want
- To discover the results of the latest randomised clinical trials in TAVI: EARLY TAVR and RHEIA
- To learn how these new data may impact clinical practice guidelines
- To discuss what will be the new frontiers in TAVI including the treatment of patients with bicuspid aortic valve and moderate aortic stenosis
Welcome and session objectives
Victoria Delgado
EARLY TAVR: what you need to know
Philippe Genereux
How will the EARLY TAVR findings impact on clinical guidelines?
Hendrik Treede
New frontiers in asymptomatic patients: case examples
Julia Mascherbauer
Discussion and audience interaction
RHEIA: what you need to know
Helene Eltchaninoff
How will the RHEIA findings impact on clinical guidelines?
Hendrik Treede
New frontiers in female patients: case examples
Discussion and audience interaction
What are the unmet clinical needs in TAVI?
Philippe Pibarot
Discussion and audience interaction
Session evaluation and key learnings
Bernard Prendergast
